JP2023089191A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023089191A5 JP2023089191A5 JP2023067121A JP2023067121A JP2023089191A5 JP 2023089191 A5 JP2023089191 A5 JP 2023089191A5 JP 2023067121 A JP2023067121 A JP 2023067121A JP 2023067121 A JP2023067121 A JP 2023067121A JP 2023089191 A5 JP2023089191 A5 JP 2023089191A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- seq
- antibody
- fragment
- light chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000012634 fragment Substances 0.000 claims 41
- 102000016550 Complement Factor H Human genes 0.000 claims 20
- 108010053085 Complement Factor H Proteins 0.000 claims 20
- 150000007523 nucleic acids Chemical class 0.000 claims 14
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 claims 12
- 108020004707 nucleic acids Proteins 0.000 claims 12
- 102000039446 nucleic acids Human genes 0.000 claims 12
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims 11
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 claims 11
- 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 claims 9
- 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 claims 9
- 230000024203 complement activation Effects 0.000 claims 7
- 230000037361 pathway Effects 0.000 claims 7
- 208000035913 Atypical hemolytic uremic syndrome Diseases 0.000 claims 6
- 206010018370 Glomerulonephritis membranoproliferative Diseases 0.000 claims 6
- 208000004451 Membranoproliferative Glomerulonephritis Diseases 0.000 claims 6
- 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 claims 6
- 102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 claims 6
- 206010064930 age-related macular degeneration Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 208000002780 macular degeneration Diseases 0.000 claims 6
- 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 claims 6
- 239000000427 antigen Substances 0.000 claims 5
- 102000036639 antigens Human genes 0.000 claims 5
- 108091007433 antigens Proteins 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- 102100022133 Complement C3 Human genes 0.000 claims 4
- 238000000338 in vitro Methods 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 101710184994 Complement control protein Proteins 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 230000008021 deposition Effects 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 230000002949 hemolytic effect Effects 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 108010028780 Complement C3 Proteins 0.000 claims 1
- 108010078015 Complement C3b Proteins 0.000 claims 1
- 101000998953 Homo sapiens Immunoglobulin heavy variable 1-2 Proteins 0.000 claims 1
- 101001008255 Homo sapiens Immunoglobulin kappa variable 1D-8 Proteins 0.000 claims 1
- 101001047628 Homo sapiens Immunoglobulin kappa variable 2-29 Proteins 0.000 claims 1
- 101001008321 Homo sapiens Immunoglobulin kappa variable 2D-26 Proteins 0.000 claims 1
- 101001047619 Homo sapiens Immunoglobulin kappa variable 3-20 Proteins 0.000 claims 1
- 101001008263 Homo sapiens Immunoglobulin kappa variable 3D-15 Proteins 0.000 claims 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims 1
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims 1
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims 1
- 102100036887 Immunoglobulin heavy variable 1-2 Human genes 0.000 claims 1
- 102100022949 Immunoglobulin kappa variable 2-29 Human genes 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000000116 mitigating effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18151726 | 2018-01-15 | ||
| EP18151726.9 | 2018-01-15 | ||
| PCT/NL2019/050018 WO2019139481A1 (en) | 2018-01-15 | 2019-01-15 | Factor h potentiating antibodies and uses thereof |
| JP2020538984A JP7471224B2 (ja) | 2018-01-15 | 2019-01-15 | Ｈ因子増強抗体及びその使用 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020538984A Division JP7471224B2 (ja) | 2018-01-15 | 2019-01-15 | Ｈ因子増強抗体及びその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023089191A JP2023089191A (ja) | 2023-06-27 |
| JP2023089191A5 true JP2023089191A5 (enExample) | 2023-12-08 |
Family
ID=60972152
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020538984A Active JP7471224B2 (ja) | 2018-01-15 | 2019-01-15 | Ｈ因子増強抗体及びその使用 |
| JP2023067121A Pending JP2023089191A (ja) | 2018-01-15 | 2023-04-17 | Ｈ因子増強抗体及びその使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020538984A Active JP7471224B2 (ja) | 2018-01-15 | 2019-01-15 | Ｈ因子増強抗体及びその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11377487B2 (enExample) |
| EP (1) | EP3740502A1 (enExample) |
| JP (2) | JP7471224B2 (enExample) |
| KR (2) | KR102896085B1 (enExample) |
| CN (1) | CN111868083B (enExample) |
| AU (1) | AU2019206207B2 (enExample) |
| BR (1) | BR112020014399A2 (enExample) |
| CA (1) | CA3088507A1 (enExample) |
| IL (1) | IL276008A (enExample) |
| MX (1) | MX2020007555A (enExample) |
| WO (1) | WO2019139481A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020014399A2 (pt) * | 2018-01-15 | 2020-12-29 | Stichting Sanquin Bloedvoorziening | Anticorpos potenciadores do fator h e seus usos |
| BR112022000739A2 (pt) * | 2019-07-17 | 2022-04-12 | Gemini Therapeutics Sub Inc | Anticorpos de potencialização de fator h e usos dos mesmos |
| CN114560941B (zh) * | 2020-11-27 | 2024-01-16 | 广东东阳光药业股份有限公司 | Cldn18.2的抗体及其应用 |
| MX2024001301A (es) * | 2021-07-30 | 2024-04-18 | Scherer Technologies Llc R P | Anticuerpos y conjugados de anticuerpo especificos para nectina 4 y metodos de uso de los mismos. |
| CN116041521B (zh) * | 2022-03-21 | 2023-11-03 | 南京蓬勃生物科技有限公司 | 靶向Siglec-15的单克隆抗体及其应用 |
| NL2032398B1 (en) * | 2022-07-06 | 2024-01-23 | Academisch Ziekenhuis Leiden | Bispecific antibody and uses thereof |
| CN118878671B (zh) * | 2024-07-04 | 2025-09-30 | 南京农业大学 | 抗兽疫链球菌SzM蛋白的猪源化单克隆抗体 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013508287A (ja) * | 2009-10-14 | 2013-03-07 | ヤンセン バイオテツク，インコーポレーテツド | 抗体を親和性成熟する方法 |
| WO2011056997A1 (en) * | 2009-11-04 | 2011-05-12 | Fabrus Llc | Methods for affinity maturation-based antibody optimization |
| KR102709811B1 (ko) * | 2014-08-20 | 2024-09-24 | 스티흐팅 산퀸 불드포르지닝 | 인자 h 강화 항체 및 그의 용도 |
| US10316093B2 (en) * | 2014-08-27 | 2019-06-11 | Memorial Sloan Kettering Cancer Center | Antibodies, compositions, and uses |
| BR112020014399A2 (pt) * | 2018-01-15 | 2020-12-29 | Stichting Sanquin Bloedvoorziening | Anticorpos potenciadores do fator h e seus usos |
| BR112022000739A2 (pt) * | 2019-07-17 | 2022-04-12 | Gemini Therapeutics Sub Inc | Anticorpos de potencialização de fator h e usos dos mesmos |
-
2019
- 2019-01-15 BR BR112020014399-5A patent/BR112020014399A2/pt unknown
- 2019-01-15 JP JP2020538984A patent/JP7471224B2/ja active Active
- 2019-01-15 AU AU2019206207A patent/AU2019206207B2/en active Active
- 2019-01-15 KR KR1020207023681A patent/KR102896085B1/ko active Active
- 2019-01-15 EP EP19714825.7A patent/EP3740502A1/en active Pending
- 2019-01-15 CN CN201980019128.3A patent/CN111868083B/zh active Active
- 2019-01-15 KR KR1020257040314A patent/KR20250171487A/ko active Pending
- 2019-01-15 WO PCT/NL2019/050018 patent/WO2019139481A1/en not_active Ceased
- 2019-01-15 US US16/961,737 patent/US11377487B2/en active Active
- 2019-01-15 CA CA3088507A patent/CA3088507A1/en active Pending
- 2019-01-15 MX MX2020007555A patent/MX2020007555A/es unknown
-
2020
- 2020-07-13 IL IL276008A patent/IL276008A/en unknown
-
2022
- 2022-06-01 US US17/829,688 patent/US20220356235A1/en active Pending
-
2023
- 2023-04-17 JP JP2023067121A patent/JP2023089191A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023089191A5 (enExample) | ||
| JP2021510523A5 (enExample) | ||
| JP2024150751A5 (enExample) | ||
| JP2024020298A5 (enExample) | ||
| JP2021184721A5 (enExample) | ||
| JP2021063090A5 (enExample) | ||
| JP2019505527A5 (enExample) | ||
| RU2019140602A (ru) | АНТИ-GARP-TGF-β-АНТИТЕЛА | |
| JP2018500014A5 (enExample) | ||
| JP2018506277A5 (enExample) | ||
| JP6410712B2 (ja) | Ｉｌ−６結合分子 | |
| JP2014158469A5 (enExample) | ||
| JP2018510617A5 (enExample) | ||
| JP2019527194A5 (enExample) | ||
| JP2019513726A5 (enExample) | ||
| RU2016137256A (ru) | АНТИТЕЛА К ФАКТОРУ КОМПЛЕМЕНТА Bb | |
| JP2024024114A5 (enExample) | ||
| JP2018529661A5 (enExample) | ||
| JP2018512402A5 (enExample) | ||
| JP2019528046A5 (enExample) | ||
| JPWO2020254827A5 (enExample) | ||
| JPWO2021224499A5 (enExample) | ||
| IL277899B2 (en) | Methods and preparations for treating yellow fever | |
| JPWO2021085252A5 (enExample) | ||
| JPWO2022226342A5 (enExample) |